Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo
Open Access
- 25 November 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (12) , 1467
Abstract
In order to enable 18F- and 177Lu-labelling within the same molecule, we introduced a silicon-based fluoride acceptor (SiFA) into the hexa-D-glutamate chain of DOTA-PP-F11N. In addition, minigastrin analogues with a prolonged as well as γ-linked D-glutamate chain were synthesised and evaluated. CCK-2R affinity (IC50, AR42J cells) and lipophilicity (logD7.4) were determined. Biodistribution studies at 24 h post-injection (p.i.) and µSPECT/CT imaging at 1, 4 and 24 h p.i. were carried out in AR42J tumour-bearing CB17-SCID mice. CCK-2R affinity of (R)-DOTAGA-rhCCK-1 to 18 was enhanced with increasing distance between the SiFA building block and the binding motif. Lipophilicity of [177Lu]Lu-(R)-DOTAGA-rhCCK-1 to 18 was higher compared to that of [177Lu]Lu-DOTA-PP-F11N and [177Lu]Lu-CP04. The respective α- and γ-linked rhCCK derivatives revealing the highest CCK-2R affinity were further evaluated in vivo. In comparison with [177Lu]Lu-DOTA-PP-F11N, [177Lu-]Lu-(R)-DOTAGA-rhCCK-9 and -16 exhibited three- to eight-fold increased activity levels in the tumour at 24 h p.i. However, activity levels in the kidneys were elevated as well. We could show that the introduction of a lipophilic SiFA moiety into the hydrophilic backbone of [177Lu]Lu-DOTA-PP-F11N led to a decelerated blood clearance and thus improved tumour retention. However, elevated kidney retention has to be addressed in future studies.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (391523415, 461577150)
This publication has 29 references indexed in Scilit:
- Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass EffectJournal of Nuclear Medicine, 2017
- Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical ModelsJournal of Nuclear Medicine, 2015
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid CarcinomaThyroid®, 2015
- 18F-Labeled Silicon-Based Fluoride Acceptors: Potential Opportunities for Novel Positron Emitting RadiopharmaceuticalsBioMed Research International, 2014
- Comparative biodistribution of 12 111In-labelled gastrin/CCK2 receptor-targeting peptidesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Medullary thyroid carcinoma: The third most common thyroid cancer reviewedOncology Letters, 2010
- Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivativesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.1999
- Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomasInternational Journal of Cancer, 1996
- C-CELLS (PARAFOLLICULAR CELLS) OF THYROID-GLAND AND MEDULLARY-THYROID CARCINOMA - REVIEW1977